Find therapies in clinical trials near you – page 37

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Semaglutide and Granisetron for Tolerability in Overweight Adults Without Diabetes

Semaglutide and Granisetron for Tolerability in Overweight Adults Without Diabetes

Long-Term Safety and Efficacy of KL1333 in Adults with Primary Mitochondrial Disease

Erdosteine in Patients With COPD

Erdosteine in Patients With COPD

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Rabies Prophylaxis in Healthy Volunteers After Rabies Virus (Inactivated) Strain Flury LEP Vaccination

Rabies Prophylaxis in Healthy Volunteers After Rabies Virus (Inactivated) Strain Flury LEP Vaccination

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

Naxitamab Added to Standard Induction Therapy for Children and Teenagers with Newly Diagnosed High-Risk Neuroblastoma

Naxitamab Added to Standard Induction Therapy for Children and Teenagers with Newly Diagnosed High-Risk Neuroblastoma

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer